Gan & Lee Pharmaceuticals (SHA:603087) said the first subject has been dosed in the first phase clinical trial of GZC8072 tablets.
The drug is an oral once-weekly peptide formulation for obesity and type two diabetes, according to a Tuesday filing with the Shanghai bourse.
Shares of the pharmaceutical company rose 1% in recent trade.